On 29 August 2016, orphan designation (EU/3/16/1718) was granted by the European Commission to Richardson Associates Regulatory Affairs Ltd, United Kingdom, for cannabidiol for the treatment of graft-versus-host disease.
The sponsorship was transferred to Salzman Group Ltd, United Kingdom, in July 2018.
|Disease / condition||
Treatment of graft-versus-host disease
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
Flat 5, 131 Fellows Road
London NW3 3JJ
Tel. +44 7743 406834
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.